Zyuds Lifesciences receives USFDA approval for DMD treatment drug
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The product will be launched in Q1FY26
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The stethoscope features high acoustic sensitivity and active noise cancellation, minimizing ambient interference to improve auscultation clarity, particularly in noisy hospital settings
Subscribe To Our Newsletter & Stay Updated